type here...
type here...
START FREE TRIAL

Healthcare

Technology & AIM&AHealthcareConsumer & RetailMiscellaneousEnergy

Moderna’s Flu Shot Won Over FDA Advisers—But Can It Win Back America?

Healthcare Ishan Majumdar -
Moderna (NASDAQ:MRNA) just landed a regulatory moment that people will argue about far beyond Wall Street. An FDA advisory committee voted that the benefits...

Novo Nordisk Earnings Pre-Mortem: The Beat May Not Be Enough!

Healthcare Ishan M. -
Novo Nordisk reports first-quarter 2026 earnings on May 6, and the market is walking into the print with unusually low expectations. Consensus cited in...
spot_imgspot_img

This Telehealth Stock Rally By RFK Jr. Looks Like Policy; It’s Actually A Margin SHIFT

Healthcare Ishan Majumdar -
Hims & Hers Health (NYSE:HIMS) did not report a surprise quarter, launch a blockbuster product, or raise guidance when...

Eli Lilly’s Foundayo & The GLP-1 Pivot From Innovation to Access Control!

Healthcare Ishan Majumdar -
Most coverage of Eli Lilly’s(NYSE:LLY) Foundayo launch has treated it like the next round in the company’s fight with...

This Biotech Stock Already Has A Blockbuster; So Why Is It ACQUIRING Another Rare Disease Asset?

Healthcare Ishan M. -
There are biotech stories that look obvious, and then there are biotech stories that quietly change shape right in...

This Medical Device Stock Just Got CRUSHED On One Hidden Number; Did Wall Street Misread It?

Healthcare Ishan Majumdar -
Boston Scientific (NYSE:BSX) spent the weekend putting forward what looked, at first glance, like a clinically solid case for...

A First-In-Class Biotech Is Still Trading Below Its Strategic Value Today

Healthcare Ishan Majumdar -
A mid-cap biotech with the first approved therapy in a large, long-underfunded liver disease category is not supposed to...

Is Align A Classic Activist Win, Or A HARDER Consumer Story?

Healthcare Ishan Majumdar -
Align Technology (NASDAQ:ALGN) has become a useful test case for a very modern market question. What happens when Wall...
Load more

Moderna’s Flu Shot Won Over FDA Advisers—But Can It Win Back America?

Healthcare Ishan Majumdar -
Moderna (NASDAQ:MRNA) just landed a regulatory moment that people will argue about far beyond Wall Street. An FDA advisory...

Novo Nordisk Earnings Pre-Mortem: The Beat May Not Be Enough!

Healthcare Ishan M. -
Novo Nordisk reports first-quarter 2026 earnings on May 6, and the market is walking into the print with unusually...

This Telehealth Stock Rally By RFK Jr. Looks Like Policy; It’s Actually A Margin SHIFT

Healthcare Ishan Majumdar -
Hims & Hers Health (NYSE:HIMS) did not report a surprise quarter, launch a blockbuster product, or raise guidance when...

Eli Lilly’s Foundayo & The GLP-1 Pivot From Innovation to Access Control!

Healthcare Ishan Majumdar -
Most coverage of Eli Lilly’s(NYSE:LLY) Foundayo launch has treated it like the next round in the company’s fight with...

This Biotech Stock Already Has A Blockbuster; So Why Is It ACQUIRING Another Rare Disease Asset?

Healthcare Ishan M. -
There are biotech stories that look obvious, and then there are biotech stories that quietly change shape right in...

This Medical Device Stock Just Got CRUSHED On One Hidden Number; Did Wall Street Misread It?

Healthcare Ishan Majumdar -
Boston Scientific (NYSE:BSX) spent the weekend putting forward what looked, at first glance, like a clinically solid case for...

A First-In-Class Biotech Is Still Trading Below Its Strategic Value Today

Healthcare Ishan Majumdar -
A mid-cap biotech with the first approved therapy in a large, long-underfunded liver disease category is not supposed to...

Is Align A Classic Activist Win, Or A HARDER Consumer Story?

Healthcare Ishan Majumdar -
Align Technology (NASDAQ:ALGN) has become a useful test case for a very modern market question. What happens when Wall...

Qiagen Just Dropped Two Magic Words—And Wall Street Heard “Buyout”

Healthcare Ishan Majumdar -
Qiagen (NYSE:QGEN) just did the thing companies do right before Wall Street starts whispering louder. On March 2, CEO...

Is Merck’s HIV Win Really About Keytruda?

Healthcare Ishan Majumdar -
When Merck & Co. (NYSE:MRK) reported Phase 3 data showing its two-drug HIV regimen of doravirine and islatravir matched...

Did Novo Nordisk’s Trial Miss Just Hand Lilly The Edge?

Healthcare Ishan Majumdar -
It has been a bruising few weeks for Novo Nordisk (NYSE:NVO). First came the clinical disappointment: CagriSema, the company’s...

Did Moderna’s Flu Rejection Signal A Deeper FDA SHIFT?

Healthcare Ishan Majumdar -
Moderna’s seasonal flu vaccine application was refused review by the FDA, triggering an immediate stock decline. The agency issued...
Load more

Baptista Research is a financial research house focused on the U.S. markets. We cover the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms.

Company

Headlines

Newsletter

Get important news delivered directly to your inbox and stay connected!

Copyright © 2026 Baptista Research. All rights reserved.